DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease
MaxCyte, a US-based global company dedicated to driving the acceleration of discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today it will present positive preclinical study results at the American Society of Gene and Cell Therapy Annual Meeting (ASGCT). The new in vitro data demonstrate the potential of MaxCyte’s cGMP-compliant proprietary delivery platform to enable CRISPR gene editing in the treatment of sickle cell disease (SCD). The ASGCT meeting will take place in Washington, DC from May 10-13, 2017.
+myBinderRelated Content
-
education & researchCoexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Fin...BACKGROUND AND PURPOSE: The recommended ...
-
news & eventsFirst systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
-
news & eventsGreenville program tries team approach to improve lifespan of sickle cell disease patientsDr. Alan Anderson who was involved with ...
-
news & eventsNIH Launches new Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global ScaleThe National Institutes of Health plans ...
-
news & eventsInvestigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
-
education & researchHydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-bas...The clinical efficacy of hydroxyurea in ...
-
news & eventsMARAC Statement: Crizanlizumab (Adakveo)July 7, 2023 - SCDAA’s Medical and Res...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.